iPPS Increases Cartilage Thickness in Phase 2 Trial
Released
Released
Announcement PDF
ASX RELEASE
18 October 2023
iPPS increases cartilage thickness at 6 months in participants with
knee osteoarthritis compared to cartilage loss in placebo group
Webinar
Paradigm Senior Management will be hosting a webinar at 11:00 AM (AEDT) to
discuss new quantitative MRI 6-month data analysis from the PARA_OA_008
phase 2 clinical trial.
When: Oct 18, 2023 11:00 AM Canberra, Melbourne, Sydney (AEDT) time
Topic: Paradigm Biopharma's PARA_OA_008 Day 168 MRI Results Webinar
Register for this webinar via:
https://us02web.zoom.us/webinar/register/WN_a1INIMLMRz67s_yScRJTIQ
After registering, you will receive a confirmation email containing information about
how to join the webinar.
Osteoarthritis (OA) leads to significant structural changes to the entire joint. Bone
remodelling, adverse inflammation of the synovium, and cartilage loss are all structural
changes in knee OA. In the natural course of the disease, it is expected that a person
with moderate to severe knee OA will lose approximately -40 µm (-0.04 mm) of cartilage
thickness in the central medial femur per year on MRI (1).
KEY HIGHLIGHTS
•
iPPS demonstrates preservation of cartilage in knee OA participants in a phase 2
study.
•
A 6-week twice weekly course of subcutaneous iPPS was shown to increase
cartilage thickness and volume and reduce bone marrow lesions and synovitis on
MRI follow-up at 6 months.
•
Participants who received iPPS had an average improvement of cartilage
thickness in the central medial femur of the knee of 60 µm (0.06 mm) at 6 months.
This is compared to placebo who lost an average -20 µm (-0.02 mm) of cartilage
thickness.
•
The twice weekly 2 mg/kg dose for 6 weeks outperformed the once weekly via MRI
assessment and is consistent with the optimal clinical dose for knee OA.
•
The results indicating a treatment effect on OA beyond the relief of symptoms
supports iPPS as a blockbuster opportunity.
•
These data are expected to be key with partnering and regulatory discussions
(TGA Provisional Approval and US FDA).
Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a
late-stage drug development company focused on delivering new therapies to address
unmet medical needs, is pleased to announce very exciting new analysis from the
phase 2 PARA_OA_008 clinical trial. demonstrating that a single 6-week treatment of
injectable pentosan polysulfate sodium (iPPS) treatment at 2mg/kg twice weekly results
in:
A) An increase in overall cartilage thickness, across all compartments of the knee, of
0.17mm (p=0.05) compared to overall decrease of -0.09mm in placebo;
B) An increase if overall cartilage volume by 1.9% (p=0.07) compared to a decrease
of -1.58% in the placebo group;
C) Resolution or decrease in of bone marrow lesions (BML) volume by 17% in the
iPPS group, whereas placebo subjects saw a 2% increase in BML and;
D) Reduced area and intensity by 1% of synovitis in the iPPS group compared to an
increase 0f 4% in synovitis intensity in placebo.
E) As previously reported (ASX release 10 October
improvements of pain and function out to 12 months.
2023)
symptomatic
The above results support that iPPS both treats the symptoms of OA and preserves and/or
regenerates joint tissues. This is significant from a commercial perspective because the
disease modifying effects of iPPS observed in the PARA_OA_008 phase 2 clinical trial
are expected to support a greater reimbursement compared to that which would be
expected for a therapeutic that only treat the symptoms of OA.
In the phase 2 clinical trial, subjects treated with iPPS (2 mg/kg twice weekly) had an
average increase of 60 µm of cartilage thickness (0.06 mm) in the central medial femur
whereas the placebo group lost an average 20 µm of cartilage (-0.02mm) in the same
region. Based on extensive literature research, this phase 2 randomised controlled trial
appears to be a world first showing:
•
A decline in disease biomarkers compared to placebo at Day 56 and Day 168;
•
Durable pain and function improvements over placebo out to Day 365, and now;
•
Increased cartilage thickness and increased cartilage volume at Day 168, while
placebo showed a reduction in both cartilage thickness and volume.
Next Steps
•
•
Paradigm has identified the optimal dose for achieving durable responses in pain,
function and patient global impression of change (PGIC). Furthermore, this dose
results in structural preservation of cartilage, and reduction in BML and synovitis.
Paradigm is progressing with the TGA Provisional Approval application which
would expedite the pathway to marketing approval in Australia.
•
•
The Company is also moving forward with the 2 mg/kg twice weekly optimal iPPS
dose for registration programs for the improvement of pain and function in knee
OA.
These data are expected to further support with partnering discussions.
Paradigm’s Managing Director, Mr Paul Rennie commented “The treatment of
osteoarthritis has not progressed for many years, with available therapies mostly treating
the symptoms of the disease for a short period. There is a high unmet need for a new OA
therapy to slow OA progression in tandem with symptomatic improvement of pain
reduction and functional improvement. In this placebo-controlled clinical trial, Paradigm’s
iPPS has now demonstrated that it not only has a durable and beneficial effect on pain,
function, and the patient’s impression of improvement out to 12 months, but we are also
seeing it is improving the underlying disease as early as 6 months following a single 6week treatment course. We look forward to presenting the PARA_OA_008 data package
to global regulatory agencies including the TGA and FDA.”
“What I find most compelling about these data, is that all participants entered the clinical
study with active structural degeneration already occurring and yet iPPS has been able
to reverse disease progression. Paradigm aims to reach agreement with the US FDA on
what data would be necessary to confirm these results in our larger phase 3 program to
include disease modifying data on our label at registration. If this is unachievable within
our current timelines and budget, the Company or our partner may undertake subsequent
additional studies (post marketing clinical studies) to achieve a disease modifying label
once iPPS is registered on the market.”
Top-line results
Osteoarthritis background
Osteoarthritis (OA) is a chronic progressive disease, over time leading to the destruction
of all joint tissues. The hallmark of OA is cartilage loss (2). As osteoarthritis progresses,
the medial side of the knee tends to lose cartilage more rapidly compared to the lateral
side.
Overall Average Change from Baseline
All Compartments/Regions
Overall cartilage thickness (mm)
Overall cartilage volume (mm3)
BML overall (mm2I)
Synovitis overall (mm2I)
iPPS-Twice-weekly
N=15
Day 168
0.17
(P= 0.05)
191.51
(P= 0.07)
-86.26
Placebo
N=22
Day 168
-0.09
-5086.13
-2707.38
-86.81
120.65
Table 1: Adjusted Change from Baseline (absolute) least squares mean (LSM) results for overall cartilage
thickness, cartilage volume, BML and synovitis size and intensity following twice weekly iPPS compared
to placebo in PARA_OA_008 at Day 168.
In the above table (Table 1) iPPS treatment was shown to increase overall cartilage
thickness and volume whilst also reducing overall bone marrow lesions and synovitis on
MRI follow up at 6 months from a 6-week treatment course of subcutaneous iPPS. The
data presented below will focus on cartilage thickness (mm) and volume (%) in the medial
compartment and overall BML and Synovitis percentage changes from baseline. All MRI
data including the lateral compartments are shown in the Appendix.
The crucial role of cartilage
Cartilage loss is generally considered to be the most important structural disease feature
of OA (Figure 1). Numerous studies have shown cartilage loss to be predictive of knee
replacement surgery for OA.
There has been substantial published research on MRI cartilage measurements showing
as osteoarthritis progresses, the medial side of the knee tends to lose cartilage more
rapidly than the lateral side (3,4). A reduction of this loss, or an increase in cartilage
thickness, may therefore delay time to total knee replacement (TKR) in an osteoarthritic
knee. Cartilage serves as a cushion and provides smooth, low-friction movement in the
knee joint. When cartilage degenerates, it can lead to bone-on-bone contact, resulting in
severe pain. Any improvement in cartilage health can help alleviate pain, improve joint
functionality, and improve the quality of life for people with knee osteoarthritis.
In knees with an OA disease severity of 2–4 on the Kellgren and Lawrence (KL) grading
scale (such as for the PARA_OA_008 participant cohort and who would already be
experiencing cartilage loss), natural OA progression would be expected to result in an
estimated continued annual loss in cartilage thickness of around 40 µm (0.04 mm) (1)
and an annual loss in cartilage volume of around -4% (6) at the central medial femur.
Figure 1. Composite image showing example front-facing (coronal) knee MRIs with highlighted cartilage
layers. Image 1 shows a healthy knee and image 2 shows an osteoarthritic knee with preserved cartilage
thickness on the lateral side and severe damage to the medial side, indicated by dAB and tAB labels.
Images from Hinterwimmer S. et al. Knee Surg Sports Traumatol Arthrosc. 2014, and Reichenbach S. et
al. Ann Rheum Dis. 2010 (7,8).
Increase in cartilage thickness with iPPS
•
The twice weekly iPPS arm consistently demonstrated an improvement in cartilage
thickness from baseline to 6 months was reported in all medial knee regions
following iPPS treatment (Figures 2 and 3).
•
The placebo arm demonstrated a loss in cartilage thickness in all medial regions
at 6 months consistent with the natural progression of OA.
•
iPPS increased the cartilage thickness in the central medial femur by 60 µm (0.06
mm) compared to a reduction of 20 µm (-0.02 mm) in the placebo group consistent
with the naturally occurring cartilage loss rate in knee OA progression (-40 µm or
0.04 mm per year).
Figure 2. Representative side-on (sagittal) MRI images from PARA_OA_008 of the knee at baseline (left
panels) and at Day 168 (right panels) from a participant receiving placebo (top panels) and a participant
receiving twice weekly iPPS (bottom panels) demonstrating changes in cartilage thickness in the medial
compartments. In the twice weekly iPPS baseline image, there is a small bone marrow lesion in the
subchondral bone (bone that is directly under cartilage) of the femur (circled in red), that is resolved at
Day 168.
Adj. CFB (abs) LS Mean Day
168
Cartilage Thickness (µm)
140
120
100
80
60
40
20
0
-20
-40
-60
iPPS 2xW
Placebo
Central Medial
Femur
Medial
Femorotibial
Compartment
Medial Tibia
Figure 3: Cartilage thickness (µm). Absolute adjusted change from baseline (CFB).
Least squares mean results by medial region in the knee. iPPS 2xW is iPPS twice weekly.
Increase in cartilage volume with iPPS
•
At 6 months, subjects receiving twice weekly iPPS showed an average increase in
cartilage volume of 3.8% in the central medial femur compared to baseline,
whereas the placebo arm showed a loss of cartilage volume of -2.2% (Figure 4).
•
This data again demonstrates iPPS is reversing the breakdown of cartilage at 6
months. This is in contrast to placebo which is showing further cartilage volume
loss from baseline consistent with the natural progression of the disease (4%
reduction in cartilage volume per year).
%CFB Mean Day 168
Cartilage Volume (% change in mm3)
7
6
5
4
3
2
1
0
-1
-2
-3
iPPS 2xW
Placebo
Central Medial
Femur
Medial
Femorotibial
Compartment
Medial Tibia
Figure 4: Average percentage (%) change from baseline (CFB) in cartilage volume (mm3) by medial
region in the knee. iPPS 2xW is iPPS twice weekly.
Reduced bone marrow lesions (BML) with iPPS treatment
Subchondral (“below the cartilage”) BMLs are a common finding on MRI, in OA. Loss of
the normal weight bearing function of articular cartilage along with shifting contact points
associated with joint laxity can cause joint overloading and is believed to result in
microtrauma which expresses as a BML (Figure 5).
Figure 5. Schematic of a knee joint showing representative locations of bone marrow lesions alongside a
representative MRI demonstrating a bone marrow lesion in the medial tibia (circled in red). Figure created
with an image from BioRender.com. MRI image, Paradigm PARA_005 clinical trial.
Like cartilage loss, BMLs have been shown to be highly predictive of knee replacement
(9–11). This means that the loss of the cushioning cartilage layer in a major weightbearing joint such as the knee can change how weight is distributed. These incessant
gradual forces on a joint where bone is moving on bone can result in cartilage breakdown
and bone remodelling to cope with the changing stresses.
Overall bone marrow lesion volume in the knee was reduced by 17.6% on average
in the iPPS twice weekly group, compared to a 2% increase in the placebo group
(Figure 6).
BML (% change from baseline)
5
%CFB Mean Day 168
•
0
-5
iPPS 2xW
Placebo
-10
-15
-20
BML Overall
Figure 6: Average percentage (%) change from baseline (CFB)
in overall bone marrow lesions. iPPS 2xW is iPPS twice weekly.
Reduced synovitis (joint inflammation) with iPPS
OA-associated synovitis is defined as an inflammation of the synovial membrane, the thin
layer of tissue that lines the joints (Figure 7). In OA, the synovial membrane can become
inflamed and thickened as the body's immune system responds to joint degeneration.
This inflammation can cause increased production of synovial fluid, which is a lubricating
fluid that normally helps the joint move smoothly. The excess synovial fluid can lead to
joint swelling and can be associated with increased pain and stiffness in the affected joint.
Figure 7. Schematic of a normal knee joint and an inflamed knee joint with synovitis.
Figure created with images from BioRender.com.
•
At 6 months in this phase 2 clinical trial, synovitis increased from baseline in the
placebo arm (4.6%) compared to a slight decrease (-1%) in the twice weekly iPPS
arm (Figure 8).
•
The observed reduction in the biomarkers of inflammation reported at Day 56 (ASX
release 4 October 2023) such as TNF-alpha and IL-6, are consistent with the
reduction in synovitis as demonstrated via quantitative MRI analysis at Day 168.
Synovitis (% change from baseline)
%CFB Mean Day 168
5
4
3
2
iPPS 2xW
1
Placebo
0
-1
-2
Synovitis Overall
Figure 8: Percentage change from baseline in overall synovitis as measured by MRI in participants
treated with twice weekly iPPS (iPPS 2xW) versus placebo.
About Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development
company driven by a purpose to improve patients’ health and quality of life by discovering,
developing, and delivering pharmaceutical therapies. Paradigm’s current focus is
developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the
treatment of diseases where inflammation plays a major pathogenic role, indicating a
need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in
osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).
Forward looking statements
This Company announcement contains forward-looking statements, including statements
regarding anticipated commencement dates or completions dates of preclinical or clinical
trials, regulatory developments and regulatory approval. These forward-looking
statements are not guarantees or predictions of future performance, and involve known
and unknown risks, uncertainties and other factors, many of which are beyond our control,
and which may cause actual results to differ materially from those expressed in the
statements contained in this presentation. Readers are cautioned not to put undue
reliance on forward-looking statements.
-ENDSAPPENDIX
Summary of studied OA biomarkers
The PARA_OA_008 trial investigating participants with knee OA who had received a 6week course of either iPPS treatment versus placebo was unique in both the breadth of
biomarkers assessed at 6 months, as well as the duration of clinical effect out to 6 and
then 12 months (Figure 9). The results from the broad range of structural and molecular
biomarkers studied in combination with the clinical results builds a convincing picture of
iPPS effects on OA disease progression.
Figure 9. Schematic of osteoarthritis biomarkers investigated in PARA_OA_008. These biomarkers are
measures of osteoarthritis, a disease of the whole joint, as such, disease pathophysiology locations are
indicative. Figure created with images from BioRender.com.
Semi-quantitative versus quantitative MRI analyses
Semi-quantitative and quantitative analyses in the context of MRI (Magnetic Resonance
Imaging) refer to different approaches for evaluating and measuring various aspects of
the images produced by MRI machines. A breakdown of the differences include:
Semi-quantitative analysis:
•
•
Semi-quantitative analysis involves a subjective assessment of MRI images.
Based on visual criteria, a score is assigned to each region.
This approach relies on broad visual interpretation, comparisons, and subjective
judgment by radiologists or researchers.
•
It is often used to evaluate features like lesion size, shape, location, and other
qualitative aspects of the image.
•
Semi-quantitative analysis is useful to establish a preliminary understanding of the
MRI changes over time.
Quantitative analysis:
•
Quantitative analysis, on the other hand, aims to provide precise numerical
measurements and data from MRI images.
•
It involves the use of specific software tools and algorithms to extract numerical
values related to parameters of interest, such as tissue volumes, or signal
intensities.
•
Quantitative analysis is more objective and less reliant on human interpretation,
making it suitable for research, clinical trials, and cases where exact
measurements are required.
Full Quantitative MRI Data Set
Cartilage thickness
Cartilage Thickness (mm) Adj. CFB (abs.) LSM results.
Compartments/Regions
iPPS-Once
N=19
Day 168
iPPS-Twice
N=15
Day 168
Placebo
N=22
Day 168
Overall Thickness (mm)
0.04
-0.09
Central Medial Femur Thickness (mm)
-0.03
0.17
(P= 0.054)
0.06
Medial Femorotibial Compartment Thickness
(mm)
Medial Tibia Thickness (mm)
-0.01
0.12
-0.04
0.02
0.06
-0.01
Central Lateral Femur Thickness (mm)
-0.02
0.03
-0.03
Lateral Femorotibial Compartment Thickness
(mm)
Lateral Tibia Thickness (mm)
0.03
0.03
-0.06
0.05
0.00
-0.03
-0.02
Overall cartilage thickness is calculated as the sum of the medial and lateral
compartments, i.e. Medial Femorotibial Compartment + Lateral Femorotibial
Compartment.
Adj. CFB (abs) LS Mean Day 168
Cartilage Thickness (µm)
200
150
100
50
iPPS 1xW
0
iPPS 2xW
-50
Placebo
-100
-150
Central
Medial
Medial Tibia
Central
Lateral
Lateral Tibia
Medial Femur Femorotibial
Lateral Femur Femorotibial
Compartment
Compartment
Overall
Cartilage volume
Cartilage Volume (mm3) Adj. CFB (abs.) LSM results.
Compartments/Regions
Overall Volume (mm3)
iPPS-Once
N=19
Day 168
iPPS-Twice
N=15
Day 168
Placebo
N=22
Day 168
-18.67
191.51
-86.81
(P= 0.073)
Central Medial Femur Volume (mm3)
-43.56
61.11
-20.01
Medial Femorotibial Compartment Volume
(mm3)
Medial Tibia Volume (mm3)
-33.68
137.32
-42.36
7.78
76.66
-22.20
Central Lateral Femur Volume (mm )
-15.85
32.43
-24.86
Lateral Femorotibial Compartment Volume
(mm3)
Lateral Tibia Volume (mm3)
13.24
51.45
-47.29
30.78
20.81
-23.46
3
Overall cartilage volume is calculated as the sum of the medial and lateral compartments,
i.e. Medial Femorotibial Compartment + Lateral Femorotibial Compartment.
Adj. CFB (abs) LS Mean Day
168
Cartilage Volume (mm3)
250
200
150
100
iPPS 1xW
50
iPPS 2xW
0
Placebo
-50
-100
-150
Central
Medial
Medial Tibia
Central
Lateral
Lateral Tibia
Medial Femur Femorotibial
Lateral Femur Femorotibial
Compartment
Compartment
Overall
Bone marrow lesions
BML (mm2I) Adj. CFB (abs.) LSM results.
Compartments/Regions
iPPS-Once
N=19
Day 168
iPPS-Twice
N=15
Day 168
Placebo
N=22
Day 168
BML Overall
303.73
-86.26
120.65
Region: Femur
316.95
-320.63
77.71
Region: Tibia
34.12
149.17
-57.47
Region: Patella
24.17
-31.14
39.31
Adj. CFB (abs) LS Mean Day 168
BML (mm2I)
400
300
200
100
iPPS 1xW
0
iPPS 2xW
-100
Placebo
-200
-300
-400
Overall
Femur
Tibia
Patella
Synovitis (inflammation)
Synovitis (mm2I) Adj. CFB (abs.) LSM results.
Compartments/Regions
iPPS-Once
N=19
Day 168
iPPS-Twice
N=15
Day 168
Placebo
N=22
Day 168
Synovitis Overall
4873.47
-5086.13
-2707.38
Region: Suprapatellar recess
1115.35
436.01
-367.38
Region: Medial recess
1161.82
-2702.41
-3232.04
Region: Hoffas fat pad
387.92
-1337.67
-806.95
Region: Lateral recess
1579.10
-1470.93
1450.95
Adj. CFB (abs) LS Mean Day 168
Synovitis (mm2I)
6000
4000
2000
iPPS 1xW
0
iPPS 2xW
Placebo
-2000
-4000
-6000
Synovitis
Overall
Suprapatellar Medial recess Hoffas fat pad Lateral recess
recess
Previously reported Day 168 molecular biomarker analysis
The structural changes demonstrated via MRI are consistent with data previously
reported (4 April 2023). These data showed reductions in molecular biomarkers of
cartilage degradation from baseline to Day 168 in iPPS-treated subjects compared to
placebo.
Molecular Biomarker
C2C (Se)
CTX II (U)
COMP (SF)
COMP (Se)
ARGS (SF)
ARGS (Se)
Day 168 iPPS v placebo
Reduced (p=0.024)
Reduced
Reduced
Reduced
Reduced (p=0.024)
Reduced
Molecular biomarkers of cartilage degradation reduced following iPPS treatment compared to placebo at
Day 168. ARGS = Aggrecan amino acids alanine, arginine, glycine, and serine; C2C = collagen type-II Cterminal cleavage neoepitope; COMP = cartilage oligomeric matrix protein; CTX II = C-terminal
crosslinked telopeptide type II collagen; Se = serum; SF = synovial fluid; U = urine.
The biomarkers C2C, CTX II, COMP, and ARGS are known to be associated with
cartilage degradation (12,13). PARA_OA_008 results demonstrated reduced biomarker
levels in the synovial fluid following iPPS treatment. These changes are consistent with
the structural changes of improvement in cartilage thickness and volume seen with MRI.
PARA_OA_008 clinical trial design
PARA_OA_008 is a phase 2 exploratory study conducted at two sites in Australia. It
explored changes in synovial fluid biomarkers with pentosan polysulfate sodium (iPPS)
treatment compared with placebo in participants with knee osteoarthritis pain.
Sixty-one (61) eligible participants were enrolled and randomly assigned to a study
intervention. Participants were administered twice weekly subcutaneous (SC) injections
of iPPS calculated for ideal body weight (IBW):
•
iPPS twice weekly: 2.0 mg/kg IBW PPS twice weekly for 6 weeks, (N = 19).
•
iPPS once weekly: 2.0 mg/kg IBW PPS once weekly + placebo once weekly for 6
weeks, (N = 20).
•
Placebo: placebo twice weekly for 6 weeks, (N = 22).
The primary objective of the study is to evaluate the effect of iPPS on synovial fluid
biomarkers associated with pain and OA disease progression in participants with knee
OA pain.
The Primary Endpoint was change from baseline at Day 56 in one or more synovial fluid
biomarkers of inflammation, pain, and joint degradation, including but not limited to
cartilage oligomeric matrix protein (COMP), c-terminal telopeptide II (CTX-II), nerve
growth factor (NGF), interleukin-1β (IL-1β), tumour necrosis factor alpha (TNFα), IL-6, a
disintegrin and metalloproteinase with thrombospondin motif 5 (ADAMTS-5), aggrecan
ARGS fragment, tissue inhibitor matrix metalloproteinase 1 (TIMP-1), CTX-I, and type II
collagen (C2C).
Secondary Objectives included evaluating clinical outcomes, determining the correlation
between synovial fluid biomarkers and clinical outcomes, determining the correlation
between biomarkers in synovial fluid and biomarkers in serum and urine, and evaluating
the effect of iPPS on serum and urine biomarkers associated with inflammation and OA
disease progression in participants with knee OA pain.
Participants in the study were asked to provide baseline pain scores using the selfassessed WOMAC Osteoarthritis Index. After patients had initiated treatment, their pain
scores were measured at predetermined timepoints from Day 11 out to Day 365 (12
months), with Day 56 the first predetermined timepoint for WOMAC assessment after the
completion of treatment (Day 39).
References
1. Eckstein F, Mc Culloch CE, Lynch JA, Nevitt M, Kwoh CK, Maschek S, et al. How do short-term rates
of femorotibial cartilage change compare to long-term changes? Four year follow-up data from the
osteoarthritis initiative. Osteoarthritis Cartilage. 2012 Nov;20(11):1250–7.
2.
Geng R, Li J, Yu C, Zhang C, Chen F, Chen J, et al. Knee osteoarthritis: Current status and research
progress in treatment (Review). Exp Ther Med. 2023 Oct;26(4):481.
3.
Cicuttini FM, Jones G, Forbes A, Wluka AE. Rate of cartilage loss at two years predicts subsequent
total knee arthroplasty: a prospective study. Ann Rheum Dis. 2004 Sep;63(9):1124–7.
4.
Eckstein F, Kwoh CK, Boudreau RM, Wang Z, Hannon MJ, Cotofana S, et al. Quantitative MRI
measures of cartilage predict knee replacement: a case-control study from the Osteoarthritis
Initiative. Ann Rheum Dis. 2013 May;72(5):707–14.
5.
Eckstein F, Wirth W. Quantitative cartilage imaging in knee osteoarthritis. Arthritis.
2011;2011:475684.
6.
Wluka AE, Forbes A, Wang Y, Hanna F, Jones G, Cicuttini FM. Knee cartilage loss in symptomatic
knee osteoarthritis over 4.5 years. Arthritis Res Ther. 2006;8(4):R90.
7.
Hinterwimmer S, Feucht MJ, Steinbrech C, Graichen H, von Eisenhart-Rothe R. The effect of a sixmonth training program followed by a marathon run on knee joint cartilage volume and thickness in
marathon beginners. Knee Surg Sports Traumatol Arthrosc Off J ESSKA. 2014 Jun;22(6):1353–9.
8.
Reichenbach S, Yang M, Eckstein F, Niu J, Hunter DJ, McLennan CE, et al. Does cartilage volume or
thickness distinguish knees with and without mild radiographic osteoarthritis? The Framingham
Study. Ann Rheum Dis. 2010 Jan;69(1):143–9.
9.
Dore D, Quinn S, Ding C, Winzenberg T, Zhai G, Cicuttini F, et al. Natural history and clinical
significance of MRI-detected bone marrow lesions at the knee: a prospective study in community
dwelling older adults. Arthritis Res Ther. 2010;12(6):R223.
10. Tanamas SK, Wluka AE, Pelletier JP, Martel-Pelletier J, Abram F, Wang Y, et al. The association
between subchondral bone cysts and tibial cartilage volume and risk of joint replacement in people
with knee osteoarthritis: a longitudinal study. Arthritis Res Ther. 2010;12(2):R58.
11. Walsh DA, Sofat N, Guermazi A, Hunter DJ. Osteoarthritis Bone Marrow Lesions. Osteoarthritis
Cartilage. 2023 Jan;31(1):11–7.
12. Hunter D, Li J, LaValley M, Bauer D, Nevitt M, DeGroot J, et al. Cartilage markers and their
association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston
Osteoarthritis Knee Study. Arthritis Res Ther. 2007;9(5):R108.
13. Huang K, Wu L. Aggrecanase and Aggrecan Degradation in Osteoarthritis: A Review. J Int Med Res.
2008 Dec;36(6):1149–60.
To learn more please visit: https://paradigmbiopharma.com
Approved for release by the Paradigm Board of Directors.
FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com
PARA_OA_008 PHASE 2 TRIAL TOP-LINE RESULTS
DAY 168 QUANTITATIVE MRI DATA ANALYSIS
Paradigm Biopharma
April 2023
2
Disclaimer
This document, together with any information communicated by Paradigm Biopharmaceuticals Ltd ASX:PAR (known as “Paradigm”, “Paradigm Biopharma” or “the
Company”), in any presentation or discussion relating to this document (collectively, “Information”) is confidential, and has been prepared by the Company on the condition
that it is for the exclusive information and use of the recipient. The Information is proprietary to Paradigm and may not be disclosed to any third party or used for any other
purpose without the prior written consent of the Company.
The Information is based upon management forecasts and reflects prevailing conditions, which are accordingly subject to change. In preparing the Information, the
Company has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources, or which was
otherwise reviewed by it. In addition, the analyses are not and do not purport to be appraisals of the assets, stock or business of the Company. Even when the Information
contains a kind of appraisal, it should be considered preliminary, suitable only for the purpose described herein and should not be disclosed or otherwise used without the
prior written consent of Paradigm. The Information is provided on the understanding that unanticipated events and circumstances may occur which may have significant
valuation and other effects.
This Company presentation contains forward-looking statements, including statements regarding anticipated commencement dates or completions dates of preclinical or
clinical trials, regulatory developments and regulatory approval.
These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of
which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are
cautioned not to put undue reliance on forward-looking
Share your feedback
Discover